Focus on factors

Abstract

Recombinant factor VIII concentrates used in the treatment of hemophilia A have provided freedom from human viral contamination for hemophiliacs who rely on frequent infusions to control bleeding. This article provides a historical perspective on the treatment of the various hemophilia types and current treatment methods for these and other inherited coagulopathies. Therapy complications associated with replacement factors and patient management issues will be addressed.